Abstract
AbstractImmunobridging is an important methodology that can be used to extrapolate vaccine efficacy estimates to populations not evaluated in clinical studies, and that has been successfully used in developing many vaccines. Dengue, caused by a mosquito-transmitted flavivirus endemic to many tropical and subtropical regions, is traditionally thought of as a pediatric disease but is now a global threat to both children and adults. We bridged immunogenicity data from a phase 3 efficacy study of a tetravalent dengue vaccine (TAK-003), performed in children and adolescents living in endemic areas, with an immunogenicity study in adults in non-endemic areas. Neutralizing antibody responses were comparable in both studies following receipt of a two-dose TAK-003 schedule (months 0 and 3). Similar immune responses were observed across exploratory assessments of additional humoral responses. These data support the potential for clinical efficacy of TAK-003 in adults.
Funder
Takeda Pharmaceuticals U.S.A.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Infectious Diseases,Pharmacology,Immunology
Reference59 articles.
1. Kempf, L., Goldsmith, J. C. & Temple, R. Challenges of developing and conducting clinical trials in rare disorders. Am. J. Med. Genet. Part A 176, 773–783 (2018).
2. Luxi, N. et al. COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety. Drug Saf. 44, 1247–1269 (2021).
3. Fink, D. WHO meeting on COVID-19 vaccines research: Immunobridging to evaluate vaccines. Vol. 2022 (2021).
4. Fritzell, B. Bridging studies. Dev. Biol. Stand 95, 181–188 (1998).
5. World Health Organization. Guidelines on Clinical Evaluation of Vaccines: Regulatory Expectations. Vol. 2022 (2017).
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献